Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | HTR6 | P50406 | 5/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234706 | 0.78 | CA2 (0.80) | CA12CA2SMN1; SMN2 | |
| SCHEMBL6737344 | 0.77 | CA2 (0.51) | CA12CA2CYP2A6PTPRCPTPN6 | |
| SCHEMBL4231613 | 0.77 | CA2 (0.51) | CA12CA2CYP2A6PTPRCPTPN6 | |
| SCHEMBL6378197 | 0.77 | CYP2A6 (0.47) | CA12CA2HTR6PIK3CDALDH1A1 | |
| SCHEMBL3793170 | 0.77 | CYP2A6 (0.47) | CA12CA2CTNNB1WNT3AALDH1A1 | |
| SCHEMBL12333390 | 0.74 | PIK3CD (0.44) | CA12CA2HTR6CTNNB1WNT3A | |
| SCHEMBL3934050 | 0.74 | HTR6 (0.61) | CA2HTR6ALDH1A1POLBMAPT | |
| SCHEMBL3795030 | 0.72 | CA2 (0.51) | CA12CA2HTR6CYP2A6PTPRC | |
| SCHEMBL5051390 | 0.72 | HTR6 (0.93) | CA12CA2HTR6ALDH1A1POLB | |
| SCHEMBL8371819 | 0.70 | IKBKB (0.48) | HTR6PIK3CDALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | CE PHARM CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | CE PHARM CO., LTD. (CN) | 2019-05-02 | — | — | US | disclosed |
| WO-2017177979-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | 中国科学院上海有机化学研究所 | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | AOC1, AOC2, AOC3 | CA12 470/4885CA2 743/4885HTR6 3576/4885 |
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | AOC1, AOC2, AOC3 | CA12 470/4885CA2 743/4885HTR6 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.